Diana Fernanda Bejarano Ramírez

Diana Fernanda Bejarano Ramírez

Auto-generated profile, based on publicly available information

Diana Fernanda Bejarano Ramírez

Hospital Universitario Fundación Santa Fe de Bogotá Bogota Colombia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in JGH Open
Verified
Journal Article
Open access
PDF file
DRDiana Fernanda Bejarano Ramírez
Diana Fernanda Bejarano Ramírez
GGGabriel Carrasquilla Gutiérrez
Gabriel Carrasquilla Gutiérrez
ARAlexandra Porras Ramírez
Alexandra Porras Ramírez
ATAlonso Vera Torres
Alonso Vera Torres
Background and Aim: Liver disease refers to a set of pathologies resulting from the interruption of liver function or the poor functioning of the liver. The estimation of morbidity and mortality due to liver disease and the context in which the disease develops are determining factors for public policies related to liver disease and its causes. The primary etiologies are cirrhosis and hepatocellular carcinoma, which are directly related to hepatitis B and C virus and alcohol consumption. Followed by hepatotoxic drug use, autoimmune hepatitis, cholestatic diseases, genetic abnormalities, and nonalcoholic steatohepatitis.Methods: A descriptive cross‐sectional study was conducted to estimate the prevalence of liver disease in Colombia between 2009 and 2016. Using the Data Warehouse–Cube of SISPRO as the primary source of the data, prevalence proportions were calculated and adjusted according to the Bennett Horiuchi method. The relationship with alcohol consumption and the index of unsatisfied basic needs based on estimates from 2005 were considered as sociodemographic variables.Results: The prevalence of liver disease differs with regard to the type of illness, sex and age of the patient, access to medical attention, and geographical location.Conclusions: As liver disease is a public health problem, it requires early intervention such as raising awareness and prevention strategies, along with postdiagnosis care channels for treatment, rehabilitation, and palliation. By implementing these strategies, public health will be positively impacted, health care resources will be optimized, and more productive years of life are available for the citizens of the country.

10 April 2025 in Liver International
Verified
Journal Article
Closed access
FPFederico Piñero
Federico Piñero
MAMargarita Anders
Margarita Anders
CBCarla Bermudez
Carla Bermudez
DADiego Arufe
Diego Arufe
AVAdriana Varón
Adriana Varón
MMManuel Mendizabal
Manuel Mendizabal

1 January 2025 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
OVOmaira Valencia
Omaira Valencia
CLCarolina López
Carolina López
EVEsteban Vanegas-Duarte
Esteban Vanegas-Duarte
CFCarolina Fillizola
Carolina Fillizola
DRDiana Fernanda Bejarano Ramírez
Diana Fernanda Bejarano Ramírez
ATAlonso Vera Torres
Alonso Vera Torres
Background: Nonalcoholic fatty liver disease (NAFLD) has a major impact on public health owing to its high morbidity and mortality due to its close relationship with several conditions, including metabolic syndrome, cirrhosis, and cancer. Therefore, this review aimed to systematically compile and summarize the scientific literature on early risk factors for NAFLD development. Methods: A systematic review of population‐based cohort studies was conducted. Studies reporting the risk factors associated with nonalcoholic steatohepatitis (NASH) and NAFLD were screened. Results: The search yielded 987 unique records, of which 196 articles were selected after title and abstract screening. A total of 39 articles were read in full text after quality analysis using Downs and Black criteria; 10 of the studies were excluded due to heterogeneity or inconclusive results. Finally, 30 publications were included in this systematic review. The review revealed that clinical conditions such as obesity, weight change, psoriasis, polycystic ovary syndrome, diabetes, thyroid disorders, and elevated serum uric acid levels increase the risk of developing nonalcoholic fatty liver. In addition, lifestyle factors such as sedentary behavior, active or passive smoking, poor sleep quality, and consumption of carbonated beverages are associated with this condition. Conclusions: Evidence was found on the association between different clinical and lifestyle risk factors and NAFLD. This supports the need for preventive, diagnostic, and therapeutic strategies to improve the metabolic, hepatic, and oncological outcomes related to this condition.

22 June 2023 in Revista Colombiana de Gastroenterología
Verified
Journal Article
Open access
PDF file
DRDiana Fernanda Bejarano Ramirez
Diana Fernanda Bejarano Ramirez
NZNelson José Alvis Zakzuk
Nelson José Alvis Zakzuk
GCGabriel Carrasquilla
Gabriel Carrasquilla
APAlexandra Porras-Ramirez
Alexandra Porras-Ramirez
ATAlonso Vera Torres
Alonso Vera Torres
Introducción: la enfermedad hepática representa una de las principales causas de morbimortalidad a nivel mundial, principalmente por cirrosis y hepatocarcinoma; sin embargo, se subestima su impacto para el paciente, sistema de salud y el país. Materiales y métodos: estudio descriptivo de corte transversal que determinó la carga económica asociada a las muertes prematuras por cirrosis y tumores primarios del hígado, mediante la valoración económica de los años productivos de vida potencialmente perdidos (APVPP) en Colombia y de enfermedad hepática en Colombia entre 2009 y 2016. Resultados y conclusiones: la carga total de enfermedad hepática representó 687,861 años de vida saludable perdidos ajustados por discapacidad (AVAD), los hombres con mayores años de vida perdidos por muerte prematura (APMP) y las mujeres con mayores años vividos con discapacidad (AVD). Las muertes por cirrosis y tumores primarios del hígado representan una carga económica que supera los 8,6 millones de dólares, lo cual refleja la necesidad de fortalecer las estrategias de intervención desde la promoción y prevención hasta el diagnóstico y tratamiento oportuno.

3 October 2026 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
DBDiana-Fernanda Bejarano-Ramirez
Diana-Fernanda Bejarano-Ramirez
AVAlonso Vera-Torres
Alonso Vera-Torres
JTJuan-Diego Torres-Flórez
Juan-Diego Torres-Flórez
CMCarlos-Federico Molina-Castaño
Carlos-Federico Molina-Castaño
Liver transplantation is a life-saving treatment for end-stage liver disease. However, the shortage of organs and complexity of donor-recipient matching re

1 January 2026 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
DBDiana Fernanda Bejarano-Ramírez
Diana Fernanda Bejarano-Ramírez
TRTatiana Roldán-Ovalle
Tatiana Roldán-Ovalle
DRDaniel Felipe Rangel-Rueda
Daniel Felipe Rangel-Rueda
LMLuis Carlos Mayor
Luis Carlos Mayor
Introduction: Epilepsy is a major neurological disorder with significant health and social implications. Understanding its burden is essential for guiding public health strategies in Colombia. Objective: To estimate the disease burden expressed in disability‐adjusted life years (DALYs) associated with epilepsy without a specific cause in Colombia from 2015 to 2020. Methods: A cross‐sectional study was conducted using data from the Individual Service Provision Registry (RIPS) and mortality records from the National Administrative Department of Statistics (DANE). DALYs were calculated as the sum of years of life lost (YLL) due to premature mortality and years lived with disability (YLD), applying disability weights from the Global Burden of Disease study. Results: Between 2015 and 2020, epilepsy accounted for 50,769 DALYs (102.4 per 100,000 inhabitants). Premature mortality represented 82% of the burden, while disability contributed 18%. Men accounted for 57% of DALYs, and the highest burden occurred in individuals aged 60 years and older. Conclusions: Epilepsy imposes a substantial health burden in Colombia, primarily driven by premature mortality. These findings underscore the need for public health policies focused on early diagnosis, timely treatment, and equitable access to care. Strategies should also address stigma reduction and resource allocation to improve outcomes and reduce YLL.